[Clinical trial of the first Polish levodopa preparation in the treatment of Parkinsonian patients].
In three neurological centres the therapeutic effects and adverse effects were compared of two levodopa preparations combined with carbidopa (25/250): 1. A foreign drug widely prescribed in Poland, and 2. Its Polish analogue produced by Polfa Stargard Works. The drugs were given to 30 patients (in two matched groups) with Parkinson disease or syndrome during 6 weeks. The trial was completed by 28 patients (one patient dropped out from each group for reasons not directly connected with the treatment). The therapeutic results were assessed on the basis of effects obtained in the NUDS and NSP scales and by measuring of the "on" phase at the beginning and at the end of the trial. In every case the global assessment of patient's condition by the patient and by the doctor was considered. The analysis of the results showed no significant statistically differences between both drugs respect to antiparkinsonian action and incidence of adverse effects.